Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
ConditionMild Stroke
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSecond Affiliated Hospital of Soochow University
About this trial
This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.
Eligibility criteria
Qualifiers
Age: 18-80 years old.
Acute mild non-cardioembolic stroke.
NIHSS score ≤5.
Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours.
Disqualifiers
Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
Intracranial hemorrhage confirmed by imaging.
Pre-stroke modified Rankin Scale (mRS) score ≥2.
Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%.
Trial design
Treatments tested in this trial
- Tirofiban+Oral Dual Antiplatelet Therapy
- Oral Dual Antiplatelet Therapy
Treatment groups
580 Participants
are divided into 2 treatment groupsLocations
18Suzhou Municipal Hospital of Anhui Province SuzhouAnhui, China
Second Hospital of Hebei Medical University ShijiazhuangHebei, China
Taikang Xian People's Hospital ZhoukouHenan, China
WuYuan County People's Hospital Bayan NurInner Mongolia, China
Sponsors and collaborators
Second Affiliated Hospital of Soochow University
Lead sponsor
Source ClinicalTrials.gov